Canadian Sec - Delayed Quote CAD

Biosenta Inc. (ZRO.CN)

Compare
0.2500 -0.0100 (-3.85%)
At close: December 31 at 2:54:09 PM EST
Loading Chart for ZRO.CN
DELL
  • Previous Close 0.2600
  • Open 0.2500
  • Bid 0.2400 x --
  • Ask 0.2500 x --
  • Day's Range 0.2300 - 0.2500
  • 52 Week Range 0.0550 - 0.8900
  • Volume 4,000
  • Avg. Volume 11,380
  • Market Cap (intraday) 7.966M
  • Beta (5Y Monthly) -0.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2400
  • Earnings Date Jan 27, 2025 - Jan 31, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Biosenta Inc. develops, manufactures, and sells chemical compounds for household and industrial applications in Canada. The company develops True, an anti-microbial, dual-action disinfectant for destroying viruses, bacteria, germs, molds, mildew, and fungi. It also manufactures and distributes Tri-Filler, an anti-microbial filler to perform filling and bulking functions. The company is based in Toronto, Canada.

www.biosenta.com

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: ZRO.CN

View More

Performance Overview: ZRO.CN

Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ZRO.CN
13.64%
S&P/TSX Composite index
17.99%

1-Year Return

ZRO.CN
13.64%
S&P/TSX Composite index
17.99%

3-Year Return

ZRO.CN
3.85%
S&P/TSX Composite index
16.12%

5-Year Return

ZRO.CN
257.14%
S&P/TSX Composite index
44.62%

Compare To: ZRO.CN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZRO.CN

View More

Valuation Measures

As of 12/31/2024
  • Market Cap

    7.97M

  • Enterprise Value

    13.33M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    37.86

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    66.31

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -217.27%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    200.98k

  • Net Income Avi to Common (ttm)

    -6.74M

  • Diluted EPS (ttm)

    -0.2400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.3k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.3M

Research Analysis: ZRO.CN

View More

People Also Watch